Preclinical data published in the Journal of Lipid Researchindicate VXX-401 is well-tolerated, with no safety signals observed, and robustly reduces LDL-C in cynomolgus monkeys.
A Phase 1 trial of VXX-401 is ongoing, with topline results expected mid-2024.
